HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), Tubulin inhibitors, ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal DiseasesDigestive System Disorders+ [4]

Active Indication

Breast CancerEarly Stage Breast CarcinomaMetastatic breast cancer+ [12]

Inactive Indication

Advanced breast cancerAdvanced HER2-Positive Breast CarcinomaAdvanced Malignant Solid Neoplasm+ [16]

Originator Organization

Genentech, Inc.

Active Organization

Hoffmann-La Roche Ltd.DSM Pharmaceuticals, Inc.

Genentech, Inc.

+ [7]

Inactive Organization

Roche Pharma AG

Roche China Holding Ltd.

License Organization

ImmunoGen, Inc.

China Resources Pharmaceutical Commercial Group Co., Ltd.

Roche Holding AG

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (22 Feb 2013),

HER2 Positive Breast Cancer

RegulationBreakthrough Therapy (United States), Fast Track (United States), Priority Review (China), Priority Review (Australia)

Structure/Sequence

Boost your research with our ADC technology data.

view full example data

Sequence Code 18481L

Source: *****

Sequence Code 44772H

Source: *****

164

Clinical Trials associated with ADO-Trastuzumab Emtansine

NCT07578116

/ Not yet recruitingPhase 3IIT

Randomized Phase III Trial of Multimodality Therapy Versus Standard of Care Systemic Therapy in HER2 Positive (HER2+) De Novo (AJCC Stage IV) Oligometastatic Breast Cancer With Response to Initial Chemotherapy

This phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted systemic therapy, compared to standard systemic therapy alone, in treating patients with HER2-positive stage IV breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or to a limited number of sites (oligometastatic). The usual approach for patients with (oligo)metastatic HER2-positive breast cancer is systemic drug treatment, which means medicines that travel through the whole body to treat both the breast and any areas where the cancer has spread. There are a number of approved HER2-targeted systemic therapy regimens available to patients. These typically include immunotherapy and/or chemotherapy. Immunotherapy drugs may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Unlike systemic therapy, locoregional therapies like surgery and radiation are focused treatments at the site of disease, delivered with the intent of sparing healthy tissues. Breast surgeries such as breast conserving therapy or total mastectomy are procedures in which the cancerous breast tissue (and healthy breast tissue in the case of total mastectomy) are surgically removed from the body. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Adding locoregional therapy, as well as metastasis-directed SBRT, to standard systemic therapy may help patients with (oligo)metastatic, HER2-positive stage IV breast cancer live longer overall or before their cancer progresses, and may help more patients achieve no evidence of disease, when compared to standard systemic therapy alone.

Start Date09 Mar 2027

Sponsor / Collaborator

SWOG

[+1]

CTRI/2026/04/107289

/ Not yet recruitingNot ApplicableIIT

Evaluation of Efficacy of Biosimilar T-DM1 in Adjuvant and Metastatic HER2-Positive Breast Cancer: A Retrospective Study from a Tertiary Cancer Centre. - RUBY STUDY

Start Date11 Apr 2026

Sponsor / Collaborator

Tata Memorial Centre

NCT07610616

/ RecruitingNot ApplicableIIT

Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids

A case-control study was conducted to evaluate the efficacy and mechanism of action of antibody-drug conjugates (ADCs) in lung cancer, utilizing patient-derived organoid (PDO)-immune co-cultures. Focusing on HER2-positive and TROP2-positive non-small cell lung cancer (NSCLC) cases, ADC candidates were screened for in vitro activity based on organoid-immune interaction models.
Key assessments included:
Tumor killing efficiency, assessed by dose-response relationships; Drug internalization (cellular uptake), as a measure of penetration into cancer cells; Antibody-dependent cellular cytotoxicity (ADCC) and bystander effect, with negative control targets employed to delineate specificity; Single-cell RNA sequencing, to profile transcriptional alterations at single-cell resolution.
Data demonstrated distinct ADC responses correlating with target expression and immune microenvironment features. The integrated approach provided cell-based evidence of ADC potency and revealed mechanistic insights-including immune-mediated cytotoxicity pathways and intracellular trafficking-supporting the rational design of clinical trials. These findings established a foundation for precision immunotherapy strategies and offered a mechanistic rationale for patient selection in HER2/TROP2-positive lung cancer.

Start Date28 Dec 2025

Sponsor / Collaborator

Guangzhou Institute of Respiratory Disease

100 Clinical Results associated with ADO-Trastuzumab Emtansine

100 Translational Medicine associated with ADO-Trastuzumab Emtansine

100 Patents (Medical) associated with ADO-Trastuzumab Emtansine

1,576

Literatures (Medical) associated with ADO-Trastuzumab Emtansine

01 Oct 2026·BREAST

Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases

Article

Author: Freedman, Rachel A ; Mayer, Erica L ; Rocque, Gabrielle ; Brufsky, Adam M ; Nangia, Julie R ; Lin, Nancy U ; Van Poznak, Catherine ; DeMeo, Michelle K ; Ruddy, Kathryn J ; Grinda, Thomas ; Heiling, Hillary M ; Rauf, Yasmeen ; Davis, Raechel ; O'Sullivan, Ciara C ; Santa-Maria, Cesar A ; Winer, Eric P ; Moy, Beverly ; Savoie, Jennifer ; Melisko, Michelle E ; Tayob, Nabihah ; Isaacs, Claudine ; Smith, Karen L ; Burns, Robyn T ; Tolaney, Sara M ; Wolff, Antonio C ; Cotter, Christine ; Rimawi, Mothaffar F ; Krop, Ian E

PURPOSE:

In TBCRC 022 (NCT01494662), neratinib and ado-trastuzumab emtansine (T-DM1) demonstrated intracranial activity among patients with HER2-positive breast cancer brain metastases. However, gastrointestinal (GI) toxicities-particularly diarrhea-were common, potentially impacting quality of life. Clinician-reported adverse event (CTCAE) grading may underestimate the patient experience. We report GI toxicities using patient-reported outcomes (PROs) in TBCRC's neratinib-T-DM1 cohort.

METHODS:

Patients received neratinib (160 mg daily) and T-DM1 (3.6 mg/kg IV every 21 days). A pre-planned analysis assessed patient-reported GI toxicities during Cycles 1-4 using the Patient-reported Outcomes Measurement Information System (PROMIS) GI Diarrhea scale, Systemic Therapy-Induced Diarrhea Assessment Tool (STIDAT), and PRO-CTCAE. Descriptive statistics and linear mixed effects models evaluated symptom trajectories over time. We evaluated agreement for PRO and clinician-reported data.

RESULTS:

Forty-four patients enrolled; all completed ≥1 PRO. GI symptom burden increased over Cycles 1-3. PROMIS scores worsened significantly by Cycle 2, with a peak mean increase of 6.62 (95% confidence interval (CI): 2.67-10.59; p = 0.002) at Cycle 3. STIDAT scores also worsened by Cycle 3 (mean change 0.50; 95%CI: 0.11-0.90; p = 0.015). Based on maximum PRO-CTCAE scores, moderate-to-severe symptoms were reported by 20.5% (diarrhea), 24.4% (appetite loss), and 41.0% (constipation). Agreement between PRO-CTCAE and clinician-reported CTCAE was low (kappa <0.2) with clinicians reporting less toxicity. PROMIS and STIDAT scores were significantly correlated.

CONCLUSION:

This GI-focused PRO analysis highlights the value of PROs in capturing patient-experienced toxicities that impact quality of life yet are underestimated by clinicians. Incorporating PROs into clinical trials can inform supportive care and prophylactic strategies.

01 Sep 2026·JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Integrated metabolomics of tumor and plasma reveals local and systemic metabolic responses to T-DM1 therapy

Article

Author: Ye, Hui ; Sang, Hua ; Wang, Guangji ; He, Xiangyu ; Shao, Chang

Comprehensive mapping of drug-induced metabolic alterations is crucial for understanding the mechanisms of targeted therapies. Antibody-drug conjugates (ADCs) such as trastuzumab emtansine (T-DM1) have revolutionized targeted cancer therapy by combining antibody specificity with cytotoxic potency. However, the metabolic reprogramming underlying their therapeutic action and systemic effects remains poorly understood. Here, we applied high-performance liquid chromatography-mass spectrometry (HPLC-MS)-based metabolomics to profile tumor and plasma metabolic alterations in a human epidermal growth factor receptor 2-positive (HER2⁺) xenograft model at 4- and 7-days following T-DM1 treatment, corresponding to the period of pronounced antitumor activity. A total of 32 significantly altered metabolites were identified in tumor tissues, mapping to pathways including tricarboxylic acid (TCA) cycle, pyrimidine metabolism and lipid metabolism, reflecting disruption in energy production and macromolecular biosynthesis. In plasma, 12 significantly altered metabolites were identified, predominantly affecting histidine, glutamine, taurine, tryptophan, and tyrosine metabolism. Integrated analysis further revealed two compartment-specific metabolites-hippuric acid and uric acid-showing opposite trends, with elevated levels in tumors and reduced levels in plasma. These bidirectional changes indicate a metabolic coupling between tumor and circulation, driven by differential utilization and excretion processes during T-DM1 response. Collectively, our findings demonstrate that T-DM1 elicits coordinated local and systemic metabolic reprogramming, providing mechanistic insights into its antitumor activity and the metabolic coupling between tumor and circulation.

01 Aug 2026·BREAST

Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence

Review

Author: Blahna, Matthew T ; Harbeck, Nadia ; Müller, Volkmar ; Anders, Carey ; Gligorov, Joseph ; Simon, Sofia ; Zanucco, Emanuele ; Duhoux, Francois P ; LeVasseur, Nathalie ; Criscitiello, Carmen ; Neuberger, Edward ; Bartsch, Rupert ; Lambertini, Matteo ; Foukakis, Theodoros ; Frenel, Jean-Sebastien ; Kaufman, Peter A ; Penault-Llorca, Frédérique ; Okines, Alicia ; Rosé, Christian ; Cameron, David A ; Sanchez-Bayona, Rodrigo ; Curigliano, Giuseppe ; Ciruelos, Eva M

BACKGROUND:

Recent years have seen rapid advances in human epidermal growth factor receptor 2 (HER2)-directed therapies for breast cancer. The shifting therapeutic landscape has presented patients and clinicians with a plethora of effective treatment options, but optimal treatment sequencing can be challenging. Tucatinib is a HER2-selective tyrosine kinase inhibitor that, when given in combination with trastuzumab and capecitabine, has demonstrated survival benefits for patients with HER2-positive (HER2+) metastatic breast cancer (MBC) pretreated with trastuzumab, pertuzumab, and trastuzumab-emtansine. Real-world data, which can supplement knowledge gained from clinical trials, has begun to emerge for tucatinib, but a comprehensive review of these studies has yet to be conducted.

METHODS:

A systematic literature review was conducted to identify studies published between January 2020 and January 2025 that evaluated the effectiveness and safety of tucatinib in routine clinical practice. Studies were eligible for inclusion if they utilized real-world data, involved patients with HER2+ MBC treated with tucatinib in any line of metastatic therapy, and assessed tucatinib's effectiveness, health-related quality of life (QoL), patient-reported outcomes (PROs), or safety.

RESULTS:

Of 468 unique references identified, 12 publications met the inclusion criteria, 3 of which were manuscripts and 9 of which were congress abstracts. Included studies were heterogeneous in sample size, the lines of therapy assessed, and outcomes reported. Tucatinib-based treatment outcomes in the post-trastuzumab deruxtecan (T-DXd) setting and for patients with brain metastases were also reported. Despite variability among studies, outcomes were broadly consistent with clinical trial findings.

CONCLUSION:

Overall, the available real-world evidence supports the clinical effectiveness of tucatinib-based therapies in HER2+ MBC, including heavily pretreated populations, patients with prior exposure to T-DXd, and those with brain metastases. However, gaps remain in the real-world data regarding the safety profile of tucatinib and its impact on health-related quality of life in routine clinical practice.

242

News (Medical) associated with ADO-Trastuzumab Emtansine

04 Sep 2026

·www.biospace.com

Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBio

Through its DualityBio deal, Roche’s Genentech hopes to create antibody-drug conjugates with payloads that can circumvent growing cancer drug resistance. Just days after announcing a deal with a South Korean company, Roche’s Genentech is now partnering with Shanghai-based DualityBio to advance next-generation antibody-drug conjugates for cancer. Under the terms of the deal, Genentech will pay $45 million upfront and set aside up to more than $1 billion in development, regulatory and commercial milestones, according to a Friday morning news release from DualityBio. The biotech will also be eligible for tiered royalties on net sales of products that reach the market. At the heart of the partnership is DualityBio’s proprietary DUPAC platform, which generates payloads that go beyond the current cytotoxic payloads and thus help to address growing drug resistance, according to the company’s website. DUPAC payloads also have a short half-life, rapidly clearing from the body. DualityBio will use DUPAC to generate antibody-drug conjugate (ADC) programs against oncology targets of Genentech’s choosing, though the partners have yet to reveal specific disease priorities. The Chinese company will be in charge of discovery and early global development, with Genentech taking over after Phase 1a studies, according to the Friday announcement. Genentech already has two FDA-approved ADCs: Polivy, indicated for diffuse large B cell lymphoma, and Kadcyla, for the treatment of certain types of breast cancer. The DualityBio deal comes just days after Genentech put up to $2.3 billion on the line to work with South Korea’s Hanmi Pharm on a non-incretin peptide candidate designed to improve the quality of weight loss. Parent company Roche also inked a previous China deal in January, committing $570 million in upfront and near-term payments to MediLink for an ADC asset. Roche, through its subsidiary Genentech, will gain access to the investigational asset HM17321, which is designed to not only elicit weight loss but also improve lean mass. DualityBio also continues the pharma’s dealing spree in cancer. In June, Roche linked up with Nurix Therapeutics in a deal that could reach $2.3 billion in value, gaining the right to co-develop and co-commercialize a BTK degrader candidate called bexobrutideg for B cell malignancies. In April, Roche deepened its relationship with C4 Therapeutics, betting more than $1 billion for two degrader-antibody conjugates for undisclosed cancer targets. The content above comes from the network. if any infringement, please contact us to modify.

ADCLicense out/in

01 Sep 2026

·www.prnewswire.com

Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers

TSY-110 is positioned to become the first biosimilar alternative to Roche's Kadcyla® (ado-trastuzumab emtansine) in major regulated markets. TAIPEI, Aug. 28, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWSE: 6838), today announced the submission of a Clinical Trial Application (CTA) to European regulatory authorities to conduct a pivotal clinical trial for TSY-110. TSY-110 is a biosimilar candidate referencing Roche's antibody-drug conjugate (ADC) Kadcyla® (ado-trastuzumab emtansine), indicated for HER2-positive metastatic and early-stage breast cancer. Designed following regulatory guidance from both US and EU authorities, the upcoming trial will evaluate the safety, tolerability, pharmacokinetics, and immunogenicity profile of TSY-110 compared with the reference product. This milestone advances Formosa Pharmaceuticals' and EirGenix's shared goal of providing cost-effective biosimilar ADC treatments to patients across regulated global markets. "Filing this CTA marks a significant achievement for Formosa Pharmaceuticals and underscores our strategic alliance with EirGenix," said Erick Co, Ph.D., President and Chief Executive Officer of Formosa Pharmaceuticals. "Antibody-drug conjugates have established themselves as mainstays in oncology, including HER2-positive breast cancer care, but patient access remains constrained by high treatment costs. Advancing TSY-110 into clinical evaluation is a momentous step toward fulfilling our goal of delivering world-class, accessible ADC options to oncologists and patients." About TSY-110 TSY-110, also designated as EG12043, is an antibody-drug conjugate (ADC) biosimilar co-developed by Formosa Pharmaceuticals and EirGenix, Inc. (TWSE: 6589). The conjugate links HER2 monoclonal antibody, trastuzumab, with a cytotoxic payload (mertansine) to selectively eradicate HER2-overexpressing cancer cells while minimizing systemic toxicity. Comprehensive preclinical assessments demonstrate high biosimilarity, drug-antibody ratio (DAR) consistency, and comparable plasma kinetics to the reference product. About HER2-Positive Breast Cancer Market HER2-positive breast cancer accounts for a significant portion of all breast cancer diagnoses globally. Approximately 2.4 million breast cancer cases were diagnosed in 2024, with HER2+ disease affecting roughly 360,000 to 480,000 of these patients based on the standard 15–20% prevalence rate. HER2-targeted therapies continue to be a prominent tool in modern oncological care. Kadcyla®, approved by the FDA in 2013, generated approximately $2.5 billion in global sales in 2025. About Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (TWSE: 6838) is a Taiwan-based biopharmaceutical company focused on the development and commercialization of novel therapeutics in ophthalmology and oncology. The company leverages its proprietary APNT® nanoparticle formulation platform to optimize drug solubility and bioavailability. Formosa's pipeline includes FDA-approved APP13007 for post-surgical ocular inflammation and pain, alongside a robust portfolio of biosimilar and novel oncology assets. For more information, please visit . About EirGenix, Inc. EirGenix Inc. (TWSE: 6589) operates on a dual business model combining CDMO with Product Development to fully leverage its cGMP manufacturing facilities and highly qualified technical staff. The company's core competitiveness stems from its dual technical capabilities in both mammalian cell line development and microbial fermentation, paired with comprehensive expertise across R&D, manufacturing, and analytics. Through a vertically integrated operational model, EirGenix maintains strict quality control and cost management and is Taiwan's largest biologics CDMO. For more information, please visit . SOURCE Formosa Pharmaceuticals Inc., 21% more press release views with Request a Demo

Drug ApprovalADC

28 Aug 2026

·www.biospace.com

Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers

TSY-110 is positioned to become the first biosimilar alternative to Roche's Kadcyla ® (ado-trastuzumab emtansine) in major regulated markets. TAIPEI , Aug. 28, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWSE: 6838), today announced the submission of a Clinical Trial Application (CTA) to European regulatory authorities to conduct a pivotal clinical trial for TSY-110 . TSY-110 is a biosimilar candidate referencing Roche's antibody-drug conjugate (ADC) Kadcyla ® (ado-trastuzumab emtansine), indicated for HER2-positive metastatic and early-stage breast cancer. Designed following regulatory guidance from both US and EU authorities, the upcoming trial will evaluate the safety, tolerability, pharmacokinetics, and immunogenicity pro TSY-110 compared with the reference product. This milestone advances Formosa Pharmaceuticals' and EirGenix's shared goal of providing cost-effective biosimilar ADC treatments to patients across regulated global markets. "Filing this CTA marks a significant achievement for Formosa Pharmaceuticals and underscores our strategic alliance with EirGenix," said Erick Co, Ph.D., President and Chief Executive Officer of Formosa Pharmaceuticals . "Antibody-drug conjugates have established themselves as mainstays in oncology, including HER2-positive breast cancer care, but patient access remains constrained by high treatment costs. Advancing TSY-110 into clinical evaluation is a momentous step toward fulfilling our goal of delivering world-class, accessible ADC options to oncologists and patients." About TSY-110 TSY-110, also designated as EG12043, is an antibody-drug conjugate (ADC) biosimilar co-developed by Formosa Pharmaceuticals and EirGenix, Inc. (TWSE: 6589). The conjugate links HER2 monoclonal antibody, trastuzumab, with a cytotoxic payload (mertansine) to selectively eradicate HER2-overexpressing cancer cells while minimizing systemic toxicity. Comprehensive preclinical assessments demonstrate high biosimilarity, drug-antibody ratio (DAR) consistency, and comparable plasma kinetics to the reference product. About HER2-Positive Breast Cancer Market HER2-positive breast cancer accounts for a significant portion of all breast cancer diagnoses globally. Approximately 2.4 million breast cancer cases were diagnosed in 2024, with HER2+ disease affecting roughly 360,000 to 480,000 of these patients based on the standard 15–20% prevalence rate. HER2-targeted therapies continue to be a prominent tool in modern oncological care. Kadcyla ® , approved by the FDA in 2013, generated approximately $2.5 billion in global sales in 2025. About Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (TWSE: 6838) is a Taiwan-based biopharmaceutical company focused on the development and commercialization of novel therapeutics in ophthalmology and oncology. The company leverages its proprietary APNT ® nanoparticle formulation platform to optimize drug solubility and bioavailability. Formosa's pipeline includes FDA-approved APP13007 for post-surgical ocular inflammation and pain, alongside a robust portfolio of biosimilar and novel oncology assets. For more information, please visit . About EirGenix, Inc. EirGenix Inc. (TWSE: 6589) operates on a dual business model combining CDMO with Product Development to fully leverage its cGMP manufacturing facilities and highly qualified technical staff. The company's core competitiveness stems from its dual technical capabilities in both mammalian cell line development and microbial fermentation, paired with comprehensive expertise across R&D, manufacturing, and analytics. Through a vertically integrated operational model, EirGenix maintains strict quality control and cost management and is Taiwan's largest biologics CDMO. For more information, please visit . View original content to download multimedia: SOURCE Formosa Pharmaceuticals Inc.,

Drug ApprovalADC

100 Deals associated with ADO-Trastuzumab Emtansine

External Link

KEGG	Wiki	ATC	Drug Bank
-	ADO-Trastuzumab Emtansine	L01XC14	DB05773

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Breast Cancer	China	Roche Pharma (Schweiz) AG	21 Jan 2020
Early Stage Breast Carcinoma	European Union	Roche Registration GmbH	15 Nov 2013
Early Stage Breast Carcinoma	Iceland	Roche Registration GmbH	15 Nov 2013
Early Stage Breast Carcinoma	Liechtenstein	Roche Registration GmbH	15 Nov 2013
Early Stage Breast Carcinoma	Norway	Roche Registration GmbH	15 Nov 2013
Metastatic breast cancer	European Union	Roche Registration GmbH	15 Nov 2013
Metastatic breast cancer	Iceland	Roche Registration GmbH	15 Nov 2013
Metastatic breast cancer	Liechtenstein	Roche Registration GmbH	15 Nov 2013
Metastatic breast cancer	Norway	Roche Registration GmbH	15 Nov 2013
HER2 Positive Breast Cancer	United States	Genentech, Inc.	22 Feb 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastroesophageal junction adenocarcinoma	Phase 3	United States	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	China	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	Japan	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	Argentina	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	Belgium	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	Brazil	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	Canada	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	Czechia	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	Finland	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	France	Hoffmann-La Roche, Inc.	03 Sep 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2026	Not Applicable	HER2 Positive Breast Cancer Adjuvant HER2-positive	187	T-DM1	wsytwbufla(fknkcqukos) = tdnwdgjgyc xijwhvlokg (lwgmtjnsye, 95 - 100)	Positive	29 May 2026
NCT02568839 (PREDIX HER2, ESMO_BC2026)	Phase 2	HER2 Positive Breast Cancer Neoadjuvant HER2-positive	164	docetaxel+trastuzumab+pertuzumab (DHP)	vbqedoncxk(qudyymkmrm) = mwidmziueo yfnrjmuyra (ekarblteec )	Positive	07 May 2026
NCT02568839 (PREDIX HER2, ESMO_BC2026)	Phase 2	HER2 Positive Breast Cancer Neoadjuvant HER2-positive	164	docetaxel+trastuzumab+pertuzumab (HER2-enriched (HER2-E))	vbqedoncxk(qudyymkmrm) = gdbhfhqtjc yfnrjmuyra (ekarblteec )	Positive	07 May 2026
ESMO_BC2026	Not Applicable	HER2 Positive Breast Cancer HER2-positive	270	Biosimilar T-DM1 (Overall)	wypxakcuqp(ewljixzjfn) = nwnkiqxbii muekqiteuk (uvfcfscced ) View more	Positive	07 May 2026
ESMO_BC2026	Not Applicable	HER2 Positive Breast Cancer Adjuvant HER2-positive	187	T-DM1	qcukzboisj(nensydnkar) = qoccdiyekx kmjbtarigd (umkhrgxvpj, 95 - 100)	Positive	07 May 2026
NCT03587740 (CTgov)	Phase 2	HER2 Positive Breast Cancer	111	T-DM1	zfogufjisl = zaimstivcn qabawiuafs (wjbazhrsqg, umnetaixjg - rurtcbaijx) View more	-	29 Apr 2026
HOPA2026	Not Applicable	Breast Cancer HER2-targeted	300	Pertuzumab	yqfxchszrh(ltjanhdaxo) = iipnolwocm acwkjiexhk (vamlzevtph ) View more	Positive	25 Mar 2026
HOPA2026	Not Applicable	Breast Cancer HER2-targeted	300	T-DM1	yqfxchszrh(ltjanhdaxo) = xliancuvsy acwkjiexhk (vamlzevtph ) View more	Positive	25 Mar 2026
ESMO_TAT2026	Not Applicable	Metastatic human epidermal growth factor 2 positive carcinoma of breast HER2-positive	101	T-DM1 Biosimilar Ujvira (metastatic)	pjtejkawsh(dsjvsskbre) = infrequent yudyqdlyct (koflpwbjgx ) View more	Positive	16 Mar 2026
SABCS2025	Not Applicable	Metastatic breast cancer HER2-positive	22	T-DM1	ruoeofyoed(csdttpacza) = associated with shorter OS (HR: 3.05), PFS (HR:4.30), and TTP (HR: 5.30) czrszbqllk (jwkcpxdlmd )	Negative	12 Dec 2025
JPRN-jRCT2031210436 (ESMO2025)	Phase 2	Extramammary Paget Disease HER2-positive	14	T-DM1 3.6 mg/kg	vxsivozdpr(usutdrbipu) = ghcqotuzer znaixpmjpk (vcilzcndsz, 57.2 - 98.2)	Positive	17 Oct 2025
NCT04744831 \| NCT03418558 \| NCT03384940 (RHEA, ESMO_GI2025) Manual	Phase 2	HER2 Positive Colorectal Cancer HER2 Positive	26	TDM-1 or trastuzumab-deruxtecan or trastuzumab/lapatinib or trastuzumab/pertuzumab or pertuzumab/TDM-1	cwbkopuupd(vtycvtojdj) = ackmryoktx eucaxgmjfu (atgmzdpkbv ) View more	Positive	03 Jul 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis